Recently, researches have demonstrated that PGRMC1 mediates doxorubicin-induced chemoresistance in uterine sarcoma [4], and PGRMC1 knockdown increases the sensitivity of colon and liver cancers to erlotinib treatment [25], thus implicating PGRMC1 as a novel and promising target for cancer therapeutics. This evidence concerns the gene PGRMC1 and uterine corpus sarcoma.